Primary glial tumours account for almost half of all central nervous system tumours (Russell & Rubinstein, 1977) with over 50% of these being the most malignant form: glioblastoma multiforme. While the addition of radiotherapy and chemotherapy has extended the mean survival time for these patients (Green et al., 1983) , all current forms of treatment are palliative and mean survival is only 1 year. Because of the poor overall results obtained with radiotherapy and chemotherapy in the treatment of malignant gliomas (Schold, 1981) and the interaction noted between these neoplasms and the immune system (Brooks et al., 1972 (Brooks et al., , 1976 (Brooks et al., , 1977 (Brooks et al., , 1978 Mahaley et al., 1977; Wilkstrand & Bigner, 1980) , immunotherapy has been a frequently proposed therapeutic adjuvant. Actual trials of immunotherapy, however, have been limited and largely unsuccessful (Albright, 1977;  Bloom, W.H. et al., 1960; Bloom, H.J.G. et al., 1973; Grace et al., 1961; Ommaya, 1976; Trouillas, 1973; Wikstrand & Bigner, 1980; Young et al., 1977) . In prior work, we have demonstrated that the production of significant levels of detectable antibodies to human glioma-associated antigens is possible without induction of experimental allergic encephalomyelitis (EAE) following repeated immunization with viable tissue-cultured cells derived from human glioblastoma multiforme tissue in non-human primates (Bigner et al., 1981b Diseases with a putative diagnosis of malignant glioma. For selection into the study, it was required that the patient had undergone subtotal resection of the tumour, exhibited a Karnofsky functional rating >70 (Karnofsky et al., 1948) , was taking no steroids, and, because viable cells were to be used, was immunocompetent. The criteria for immunocompetence were: a WBC >5,000cellsmm-3 and either a >5 mmm cutaneous hypersensitivity response (DHR); response to at least one of 3 recall antigens: streptokinase-streptodornase (SK-SD) ( Steptokinase 100,000 units and steptodornase 25,000 units/vial) (1:10 dilution) (Lederle, London), purified protein derivative (PPD) (middle strength) (Evans Medical, Liverpool), and candida antigen undiluted 100,000unitsml-1 (Bencard, Brentford) at 48 h; or to 2 of 5 antigens in the LIF assay (Bean et al., 1983) . The final criterion required for treatment was a major HLA mismatch with the immunizing glioma cell line.
The glioma line U251-MG (for details, see below) and the patients were typed using 150 antisera identifying 11 A locus, 18 B locus and 6 locus antigens. The antisera included those used in the 7th and 8th Histocompatibility Testing Workshops (Bodmer et al., 1978; Terasaki, 1980) as well as local sera. The glioma line was also more extensively tested for all the currently identified HLA antigens using 9th Histocompatibility Workshop antisera (Albert & Mayr, 1984) . All the tests were carried out using the standard NIH techniques with cytofluorochromasia (Bodmer & Bodmer, 1979) .
In U251-MG only 3 out of a possible 6 HLA antigens were identified. This may mean either that the line is homozygous for HLA or that the antigens were not identified. The number of mismatches is given for each case (Table I ). The number of certain mismatches assumes that U251-MG did in fact carry the three unidentified HLA ©) The Macmillan Press Ltd., 1985 (Bigner et al., 1981a) because of its expression of glial fibrallary acidic protein (GFAP), tumorigenicity in athymic mice, lack of induction of EAE with hyperimmunization in non-human primates and its induction of cross reacting glioma-associated antibodies in primates (Bigner et al., 1981b; Wikstrand & Bigner, 1980; Bigner et al., 1981a; Bullard et al., 1981a Bullard et al., , 1981b Following surgery, all patients were also treated with the most effective form of conventional therapy which consisted of a combination of radiotherapy and chemotherapy. For this protocol, radiation was administered to the whole head in fractionated doses to a total dose of 40-50Gy over a 4-6 week period beginning 2-4 weeks after operation. From 2-6 weeks after completion of radiation therapy, patients began chemotherapy. Chemotherapy consisted of vincristine sulphate (VCR) (Oncovin, Lilly) 1.4 mgm -2 i.v. as a single dose, 1-(2-choloethyl)-3-cyclohexyl-1-nitrosourea (CCNU) (Lundbeck, UK) 110 mgm-2 as a single oral dose and procarbazine (PCB) (Natulan, Roche) 60mgm-2 given orally each day for 10 days. This cycle was repeated every 6 weeks so that patients received 12 cycles over an 18-20 month period. Patients were reviewed clinically and haematologically every 6 weeks on an outpatient basis. Karnofsky scores were recorded and FBC, electrolytes and liver enzymes levels were routinely monitored. CT scans were performed every 3 months during active therapy and every 6 months following completion of therapy.
Immunotherapy was begun one week following surgery. Subsequent booster doses consisting of 107 tumour cells alone were inoculated one week prior to the chemotherapy treatments every 6 weeks. Blood samples for serum and haematological analyses were obtained prior to each inoculation. Disease progression was defined as a marked deterioration in clinical status, which was often accompanied or preceded by a worsening in the CT scan. CT evaluation was based upon the classification used by Levin et al. (1977) , ranging from markedly better (3 +) to markedly worse (-3).
The complement-dependent cytotoxic antibody
[14C]nicotinamide release assay and the minor variations of the assay method introduced for use with cultured human glioma cells have been previously described (Wikstrand et al., 1977 Of the 5 patients selected for the preliminary study, two were excluded early in the trial because of either poor tolerance of radiotherapy or the occurrence of a pulmonary embolus. The 3 remaining patients (Tables II and III) received between 6-11 courses of chemotherapy and 9-17 immunotherapy courses following whole head irradiation (Table III) . The intervals from initial surgery to clinical deterioration for these 3 patients ranged from 309 days to 729 days while total survival time ranged from 383-934 days. Two of these patients, (A.J. and A.F.) maintained high Karnofsky levels until death (Figure 1 Serial CT scans were performed in these patients. In all 3 of the patients, following surgery and irradiation there was a significant improvement in the CT scan (Figure 1) . Initially, in one patient, A.F., only postoperative changes were seen, while the other 2 patients maintained small amounts of residual tumour. In patients A.F. and A.J., clinical deterioration was preceded -3 months by radiographic evidence of tumour recurrence. Patient M.P., however, failed to show evidence of tumour recurrence despite significant clinical deterioration. The CT findings correlated generally with the findings at autopsy. Of the 3 patients receiving immunotherapy, two, A.F. and M.P., produced levels of cytotoxic antibody against the immunizing cell line U251-MG (Figure 1 ). The 3rd patient (A.J.) produced only negligible levels of antibody as detected by [14C] nicotinamide release assay throughout the course of the immunotherapy. As shown in Figure   1 , the responses of patients A.F. and M.P. were quite similar, peaking between the 5th and 6th immunizations, followed by an abrupt and irreversible fall in detectable complement-dependent cytolytic antibody. In both cases, the observed drop in cytolytic activity followed the 4th course of chemotherapy.
The antibody titres of both patients at the peak of their respective responses were low (Figure 2) . The 50% specific release endpoint of unabsorbed serum was 1/32 for patient A.F. and -1/100 for patient M.P. Because of low antibody titre, serial absorption to completeness as performed by Mahaley et al. (1983) was not done; instead, either two absorptions with pooled human PBL (2x 107cells) or a single absorption with 107 2-T sarcoma cells of peak response sera from patients A.F. and M.P. were performed. Either absorbent removed . 50% of the cyto!ytic activity of both of these sera (Figure 2) (Wikstrand & Bigner, 1977; Wikstrand et al., 1979) (Febvre et al., 1972) . Whether the selection of potentially immunocompetent patients plays a role in this response to therapy remains more speculative than the use of adjuvant. Other than the serologic response of these 2 patients and the local reactions, there was no evidence that a significant immunologic reaction occurred. In none of the 3 patients was there any leukocytosis, development of increased reaction to glioma extracts on LIF assay or an increase in lymphocytic infiltration of their tumours at autopsy or second surgical procedure. But because all 3 patients underwent cytotoxic chemotherapy during this period of time, it is hard to clearly assess the interaction between these two phenomena.
It may be speculated that the prolonged survival seen in the 2 patients who mounted serologic responses is related to the immunotherapy. However, these patients were young and had high initial Karnofsky scores, both of which influence the natural history of the disease. A similar finding of prolonged survival has been reported from a separate study using irradiated cells from this same immunizing cell line in combination with BCG-cw, Levamisole and chemotherapy with BCNU (Mahaley et al., 1983) . In that study, 20 patients with malignant gliomas were selected for active immunization with either U25 1-MG cell line or D54-MG cell line, both of which were derived from malignant gliomas. Patients who were inoculated with the U251-MG cell line had a longer survival time when compared to those inoculated with D54-MG cell line or when compared with historical controls treated with Levamisole, radiation therapy and chemotherapy. Differences in titre between viable versus irradiated cells were not significantly different when both were used in non-human primates (Wikstrand & Bigner, 1981 ). This appears to also be true in humans, although only limited data exist on this point. Although no toxicity was seen in this study utilizing live cells, the lack of definite advantage and the potential for complications would suggest that future studies should display irradiated cells. While no definitive conclusions can be drawn from these 2 small series, further clinical and immunologic evaluation of active immunotherapy would appear to be warranted.
The question of haematologic compromise is also suggested from the data obtained in these patients. However, comparative haematologic data from 126 patients receiving similar chemotherapy were essentially identical. Patients undergoing immunotherapy were also subject to phlebotomy twice as often as chemotherapy patients, which may have played a significant role in their haematologic compromise. This, in association with the use of cytotoxic drugs, may explain this phenomenon. Why 2 of the 3 patients also developed episodes of anaemia in association with elevated sedimentation rates is unexplained despite extensive evaluation. No evidence of infection was seen and only generalized bone marrow depression compatible with chemotherapy was noted. At autopsy, neither of these patients demonstrated any evidence of allergic encephalomyelitis or a significant autoimmune reaction.
In summary, *adjuvant therapy of malignant gliomas with viable, HLA mismatched glioma cells appears to be a safe form of therapy that deserves further evaluation because of its theoretical potential. In this study, two of three patients receiving immunotherapy had prolonged survival and evidence of a serologic response to the immunizing cell line. No evidence of local tumour growth or an allergic encephalitis was seen.
